354 related articles for article (PubMed ID: 16128193)
1. [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Krüger K
MMW Fortschr Med; 2005 Aug; 147(31-32):28-30. PubMed ID: 16128193
[TBL] [Abstract][Full Text] [Related]
2. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Hochberg MC
Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
[TBL] [Abstract][Full Text] [Related]
3. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Gibofsky A
J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pharmacology of the selective COX-2 inhibitors].
Burian M; Geisslinger G
Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
[TBL] [Abstract][Full Text] [Related]
5. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
Einecke D
MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
[No Abstract] [Full Text] [Related]
6. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP; Curtis SP; Bolognese JA; Laine L;
Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
McCormack PL
Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
Bingham CO; Smugar SS; Wang H; Peloso PM; Gammaitoni A
Pain Med; 2011 Mar; 12(3):352-61. PubMed ID: 21332932
[TBL] [Abstract][Full Text] [Related]
11. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
12. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
13. [Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].
Tsurko VV; Preobrazhenskiĭ DV; Ob ukhova OA
Ter Arkh; 2003; 75(5):64-70. PubMed ID: 12847902
[No Abstract] [Full Text] [Related]
14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
15. Selective COX-2 inhibitors.
Pasero C; McCaffery M
Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
[No Abstract] [Full Text] [Related]
16. [Etoricoxib (Arcoxia)].
Leclercq P; Malaise MG
Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
[TBL] [Abstract][Full Text] [Related]
17. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Baraf HS
Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
[TBL] [Abstract][Full Text] [Related]
19. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
Krüger K
Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746
[No Abstract] [Full Text] [Related]
20. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
